Imcyse technology addresses diseases that represent a huge medical need, in terms of number of diseases and patients, clinical severity and unsatisfactory therapeutic options. There is potential for early treatment and cure of severe chronic diseases, and subsequently to induce regeneration of damaged cells and organs.
The main target indications encompass severe autoimmune diseases such as type 1 diabetes and multiple sclerosis. Existing therapies can at-best attenuate the disease symptoms and slow down their progress, but often with frequent and severe adverse events. There is no therapeutic opportunity for cure.
In addition to autoimmune diseases, Imcyse technology has demonstrated the efficacy of the concept in animal models of allergies and in prevention of skin graft rejection.
Imcyse technology can also be used as « add-on » therapy to other drugs or biologics to prevent development of immunogenicity and loss of efficacy upon chronic administration - such as monoclonal antibodies, replacement enzymes or coagulation factors. Similarly, Imcyse technology can eliminate the immune response against viral vectors, that are used in gene therapy.
Imcyse technology has therefore the potential to address numerous important unmet medical issues.